There is troubling news for Pfizer and cancer med Xtandi. Pfizer and partner Astellas have given up trials of Xtandi in breast cancer.
In the aftermath of its Mystic data release, AstraZeneca found a champion Thursday in Neil Woodford, the prominent U.K. fund manager.
Merck, which was a victim in the June global cyberattack, has yet to fully restore its manufacturing and R&D operations since they were hit.
Consumer health businesses are supposed to be safe havens for drugmakers, but GSK and Bayer in the last two days have reported weak consumer sales.
GlaxoSmithKline’s decision to explore a sale for its rare disease portfolio offers both an opportunity and a warning sign.
Facing mounting pressure to make an acquisition, Gilead executives were likely relieved to report an unexpected surge of second-quarter growth.
Roche's highly touted new multiple sclerosis drug Ocrevus surprised the market by generating $200 million in its first quarter on the market.
New CEO Emma Walmsley is putting her stamp on GSK with plans to get more from the pharmaceutical unit, which includes a major overhaul of R&D.
Amgen beat revenue expectations in second-quarter earnings released Tuesday, but some analysts think the company needs M&A. Its executives? Not so much.
Eli Lilly beat sales estimates in the second quarter, but the pressure is on for the company to continue to innovate.